Vertex Pharmaceuticals target price raised to $640 from $615 by UBS
VRTX•UBS raised its target price for Vertex Pharmaceuticals to $640 from $615.
Related News
LTC tops 2026 mid-point shop acquisition guidance with $62 million transaction, welcomes Grace Management
LTC•
U.S. September factory orders data
SPY•
DuPont raises annual profit forecasts, sees upbeat Q4 on healthcare, aerospace strength
DD•
XMax announces $30 million share repurchase program
XMAX•
McDonald’s taps law firm White & Case in cases alleging AI-powered price-fixing
MCD•